Linked Life Data

11345781

Source:http://linkedlifedata.com/resource/pubmed/id/11345781

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11345781rdf:typepubmed:Citationlld:pubmed
pubmed-article:11345781lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:11345781lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:11345781lifeskim:mentionsumls-concept:C1332225lld:lifeskim
pubmed-article:11345781lifeskim:mentionsumls-concept:C0544452lld:lifeskim
pubmed-article:11345781lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:11345781lifeskim:mentionsumls-concept:C0015730lld:lifeskim
pubmed-article:11345781lifeskim:mentionsumls-concept:C0242602lld:lifeskim
pubmed-article:11345781lifeskim:mentionsumls-concept:C0205265lld:lifeskim
pubmed-article:11345781lifeskim:mentionsumls-concept:C1527428lld:lifeskim
pubmed-article:11345781lifeskim:mentionsumls-concept:C1555582lld:lifeskim
pubmed-article:11345781pubmed:issue3lld:pubmed
pubmed-article:11345781pubmed:dateCreated2001-5-10lld:pubmed
pubmed-article:11345781pubmed:abstractTextHigh-dose therapy with peripheral blood stem cell transplantation (HDT/PBSCT) was performed as one aspect of front-line therapy in patients with poor-risk aggressive non-Hodgkin's lymphoma (high-intermediate/high risk) according to the age-adjusted international prognostic index (aaIPI). Twenty-nine patients were enrolled in this study between November 1994 and March 1999. CHOP + etoposide (CHOP-E) was used as an initial chemotherapy and as a chemotherapy agent for the purpose of cell harvesting. Peripheral blood stem cells were harvested from 17 patients, and HDT with CEC (carboplatin, etoposide, cyclophosphamide)/PBSCT was performed in 11 patients. Eighteen patients dropped out, including five for whom CHOP-E therapy was ineffective and 5 who did not give consent for cell harvesting or HDT/PBSCT. CHOP-E therapy produced complete remission (CR) in 15 out of 26 patients (58%) after discounting the 3 who were ineligible among the 29 who were initially enrolled. The median observation period after PBSCT in the 11 patients who underwent HDT/PBSCT was 25 months (3 to 50 months), and the 3-year disease-free survival rate was 73%. No serious complications associated with the transplantation were observed. We were able to confirm the feasibility and safety of HDT/PBSCT as one form of front-line therapy for aggressive non-Hodgkin's lymphoma in patients under 60 years of age.lld:pubmed
pubmed-article:11345781pubmed:languagejpnlld:pubmed
pubmed-article:11345781pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11345781pubmed:citationSubsetIMlld:pubmed
pubmed-article:11345781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11345781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11345781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11345781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11345781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11345781pubmed:statusMEDLINElld:pubmed
pubmed-article:11345781pubmed:monthMarlld:pubmed
pubmed-article:11345781pubmed:issn0485-1439lld:pubmed
pubmed-article:11345781pubmed:authorpubmed-author:FujimotoMMlld:pubmed
pubmed-article:11345781pubmed:authorpubmed-author:HayashiKKlld:pubmed
pubmed-article:11345781pubmed:authorpubmed-author:NasuKKlld:pubmed
pubmed-article:11345781pubmed:authorpubmed-author:OhnoHHlld:pubmed
pubmed-article:11345781pubmed:authorpubmed-author:DoiSSlld:pubmed
pubmed-article:11345781pubmed:authorpubmed-author:FukuharaSSlld:pubmed
pubmed-article:11345781pubmed:authorpubmed-author:MoriguchiTTlld:pubmed
pubmed-article:11345781pubmed:authorpubmed-author:KonakaYYlld:pubmed
pubmed-article:11345781pubmed:authorpubmed-author:KitajimaHHlld:pubmed
pubmed-article:11345781pubmed:authorpubmed-author:ArimaNNlld:pubmed
pubmed-article:11345781pubmed:authorpubmed-author:TsudoMMlld:pubmed
pubmed-article:11345781pubmed:authorpubmed-author:KatsuradaTTlld:pubmed
pubmed-article:11345781pubmed:issnTypePrintlld:pubmed
pubmed-article:11345781pubmed:volume42lld:pubmed
pubmed-article:11345781pubmed:ownerNLMlld:pubmed
pubmed-article:11345781pubmed:authorsCompleteYlld:pubmed
pubmed-article:11345781pubmed:pagination191-8lld:pubmed
pubmed-article:11345781pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:meshHeadingpubmed-meshheading:11345781...lld:pubmed
pubmed-article:11345781pubmed:year2001lld:pubmed
pubmed-article:11345781pubmed:articleTitle[High-dose therapy and peripheral blood stem cell transplantation for patients with aggressive non-Hodgkin's lymphoma remaining in initial remission: results of a feasibility study].lld:pubmed
pubmed-article:11345781pubmed:affiliationDepartment of Hematology, Kishiwada City Hospital.lld:pubmed
pubmed-article:11345781pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11345781pubmed:publicationTypeEnglish Abstractlld:pubmed